Perspective Therapeutics
CATX
105 hedge funds and large institutions have $385M invested in Perspective Therapeutics in 2024 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 48 closing their positions.
209% more capital inflows, than outflows
Capital inflows: $305M | Capital outflows: $98.8M
88% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 17
15.08% more ownership
Funds ownership: 42.24% → 57.32% (+15%)
2% more funds holding
Funds holding: 103 → 105 (+2)
8% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 48
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$45.3M |
| 2 |
Avidity Partners Management
Dallas,
Texas
|
+$43.9M |
| 3 |
BlackRock
New York
|
+$39M |
| 4 |
Commodore Capital
New York
|
+$36.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.5M |
| 2 |
Hills Bank & Trust
North Liberty,
Iowa
|
-$12.3M |
| 3 |
Laurion Capital Management
New York
|
-$10.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.41M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$8.87M |
CATX Hedge Fund Activity: Q2 2024 in Review
105 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2024, worth a combined $385M — up 30% from $296M a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new CATX positions and 48 closed out — a net gain of 4 holders — while 32 added to existing stakes and 17 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $45.3M. The largest seller was Point72 Asset Management, cutting an estimated $16.5M.
- 105 institutional investors held Perspective Therapeutics (CATX) as of Q2 2024, up from 103 in Q1 2024.
- Funds reported $385M of Perspective Therapeutics stock for Q2 2024, up 30% quarter-over-quarter.
- 52 funds opened new Perspective Therapeutics positions in Q2 2024 and 48 closed out, a net change of +4 holders.
- The largest Perspective Therapeutics buyer in Q2 2024 was Janus Henderson Group, an estimated $45.3M added.
- The largest Perspective Therapeutics seller in Q2 2024 was Point72 Asset Management, an estimated $16.5M sold.
Based on aggregated 13F filings for Q2 2024.